Key Points
- Insider transaction: Soleil Boughton sold 3,458 Hims & Hers shares for approximately $97,965 under a pre-arranged Rule 10b5-1 plan, reducing the position by 1.1% while retaining 310,506 shares.
- Financial performance: Second-quarter revenue rose 38.2% year over year to $753.2 million, exceeding estimates, but the company reported an adjusted loss of $0.37 per share versus the expected $0.05 loss.
- Investor concerns: Analysts maintain a consensus “Hold” rating with a $32.50 target price, while regulatory and securities-litigation allegations add uncertainty despite growth opportunities in weight-loss treatments, international markets and AI.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,458 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $28.33, for a total value of $97,965.14. Following the sale, the insider owned 310,506 shares in the company, valued at approximately $8,796,634.98. The trade was a 1.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Soleil Boughton also recently made the following trade(s):
- On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.
Hims & Hers Health Stock Performance
Hims & Hers Health stock opened at $27.77 on Friday. The firm's 50 day simple moving average is $31.79 and its 200-day simple moving average is $26.74. The company has a market cap of $6.48 billion, a P/E ratio of -44.08 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm's revenue was up 38.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.17 EPS.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. UBS Group set a $23.00 target price on Hims & Hers Health in a report on Friday, May 22nd. BTIG Research reissued a "neutral" rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Morgan Stanley raised their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Finally, Bank of America increased their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $32.50.
Check Out Our Latest Stock Report on Hims & Hers Health
Hims & Hers Health News Roundup
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Hims & Hers raised its 2026 revenue outlook after second-quarter revenue increased 38.2% year over year to $753.2 million, exceeding analyst expectations. The company’s growth drivers include weight-loss treatments, international expansion and artificial intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
- Neutral Sentiment: Analyst sentiment remains cautious, with brokerages maintaining a consensus “Hold” rating. While some analysts cite weight-loss, international and AI momentum, margin pressure and uncertainty surrounding FDA oversight remain concerns. Analysts Have Conflicting Sentiments on These Healthcare Companies
- Negative Sentiment: Multiple law firms publicized a securities class-action lawsuit against Hims & Hers and certain executives. The case covers investors who purchased shares between August 4, 2025, and July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. The repeated announcements amplified concerns about potential litigation costs, regulatory penalties and reputational damage. Kaplan Fox Class Action Announcement
- Negative Sentiment: The litigation follows allegations tied to an FTC complaint, including potentially deceptive privacy and billing practices. Allegations cited in the filings include sharing consumer health information with advertising platforms and charging for prescriptions shortly after intake submissions. These claims raise the risk of enforcement actions, fines and additional compliance costs, although they remain allegations.
- Negative Sentiment: An insider sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced the insider’s position by 1.1%, making it a relatively small and scheduled transaction, but it nevertheless adds a modest negative signal amid the broader legal concerns. Insider Trading Information
Institutional Trading of Hims & Hers Health
A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Versant Capital Management Inc boosted its stake in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health in the 1st quarter worth approximately $30,000. Finally, Greenline Wealth Management LLC acquired a new stake in Hims & Hers Health in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
